Education
About Us
Working with TipRanks
Follow Us
Sinopharm Group Co., Ltd. Unsponsored ADR Class H (SHTDY)
:SHTDY
RESEARCH TOOLSreports
Total Valuation
Sinopharm Group Co has a market cap or net worth of $7.33B. The enterprise value is $286.34B.
Market Cap$7.33B
Enterprise Value$286.34B
Share Statistics
Sinopharm Group Co has 268,362,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding268,362,150
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Sinopharm Group Co’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 5.82%.
Return on Equity (ROE)0.09
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)5.82%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee5.40M
Profits Per Employee129.38K
Employee Count108,217
Asset Turnover1.49
Inventory Turnover8.66
Valuation Ratios
The current PE Ratio of Sinopharm Group Co is 8.77. Sinopharm Group Co’s PEG ratio is 0.69.
PE Ratio8.77
PS Ratio0.00
PB Ratio0.80
Price to Fair Value0.78
Price to FCF2.93
Price to Operating Cash Flow2.59
PEG Ratio0.69
Income Statement
In the last 12 months, Sinopharm Group Co had revenue of 584.51B and earned 7.05B in profits. Earnings per share was 11.30.
Revenue584.51B
Gross Profit44.26B
Operating Income16.19B
Pretax Income14.00B
Net Income7.05B
EBITDA21.47B
Earnings Per Share (EPS)11.30
Cash Flow
In the last 12 months, operating cash flow was 19.51B and capital expenditures -1.02B, giving a free cash flow of 17.00B billion.
Operating Cash Flow19.51B
Free Cash Flow17.00B
Free Cash Flow per Share63.36
Dividends & Yields
Sinopharm Group Co pays an annual dividend of $0.471, resulting in a dividend yield of 4.01%
Dividend Per Share$0.471
Dividend Yield4.01%
Payout Ratio30.04%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.30
52-Week Price Change-14.83%
50-Day Moving Average11.41
200-Day Moving Average12.14
Relative Strength Index (RSI)53.35
Average Volume (3m)203.00
Important Dates
Sinopharm Group Co upcoming earnings date is Sep 1, 2025, TBA Not Confirmed.
Last Earnings DateApr 25, 2025
Next Earnings DateSep 1, 2025
Ex-Dividend DateJun 17, 2025
Financial Position
Sinopharm Group Co as a current ratio of 1.39, with Debt / Equity ratio of 102.24%
Current Ratio1.39
Quick Ratio1.14
Debt to Market Cap1.15
Net Debt to EBITDA1.03
Interest Coverage Ratio5.92
Taxes
In the past 12 months, Sinopharm Group Co has paid 3.58B in taxes.
Income Tax3.58B
Effective Tax Rate0.26
Enterprise Valuation
Sinopharm Group Co EV to EBITDA ratio is 15.43, with an EV/FCF ratio of 34.58.
EV to Sales0.57
EV to EBITDA15.43
EV to Free Cash Flow34.58
EV to Operating Cash Flow28.68
Balance Sheet
Sinopharm Group Co has $43.33B in cash and marketable securities with ¥101.06B in debt, giving a net cash position of $57.72B billion.
Cash & Marketable Securities$43.33B
Total Debt¥101.06B
Net Cash$57.72B
Net Cash Per Share$215.09
Tangible Book Value Per Share$37.08
Margins
Gross margin is 8.59%, with operating margin of 2.77%, and net profit margin of 1.21%.
Gross Margin8.59%
Operating Margin2.77%
Pretax Margin2.40%
Net Profit Margin1.21%
EBITDA Margin3.67%
EBIT Margin2.86%
Analyst Forecast
The average price target for Sinopharm Group Co is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-3.62%
EPS Growth Forecast-23.24%